ES2564252T3 - Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos - Google Patents

Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Download PDF

Info

Publication number
ES2564252T3
ES2564252T3 ES11745672.3T ES11745672T ES2564252T3 ES 2564252 T3 ES2564252 T3 ES 2564252T3 ES 11745672 T ES11745672 T ES 11745672T ES 2564252 T3 ES2564252 T3 ES 2564252T3
Authority
ES
Spain
Prior art keywords
seq
lcdr1
lcdr2
hcdr1
hcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11745672.3T
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2564252T3 publication Critical patent/ES2564252T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo monoclonal anti-N3pGlu Aß humano diseñado por ingeniería genética o fragmento de unión al antígeno del mismo, que comprende una región variable de cadena ligera (LCVR) y una región variable de cadena pesada (HCVR), en el que dicha LCVR comprende los polipéptidos LCDR1, LCDR2 y LCDR3, y HCVR comprende los polipéptidos HCDR1, HCDR2 y HCDR3 que se seleccionan entre: a) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYDFTRYYIN (SEC ID Nº 6), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGITVY (SEC ID Nº 9); b) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); c) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGETVY (SEC ID Nº 41); d) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLGS (SEC ID Nº 35), LCDR3 es VQGTHYPFT 5 (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); y e) LCDR1 es KSTRSLLYSRSKTYLN (SEC ID Nº 45), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8), y HCDR3 es EGVTVY (SEC ID Nº 46).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11745672.3T 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Active ES2564252T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12
US373026P 2010-08-12
PCT/US2011/046994 WO2012021469A1 (en) 2010-08-12 2011-08-09 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2564252T3 true ES2564252T3 (es) 2016-03-21

Family

ID=44543826

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11745672.3T Active ES2564252T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Country Status (41)

Country Link
US (2) US8679498B2 (es)
EP (3) EP2603523B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN103068848B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK2603523T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2564252T3 (es)
FI (1) FIC20250038I1 (es)
FR (1) FR25C1055I1 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE037524T2 (es)
IL (2) IL285226B2 (es)
LT (3) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME03032B (es)
MX (2) MX342782B (es)
MY (2) MY181969A (es)
NL (1) NL301359I2 (es)
NO (2) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL3042917T3 (es)
PT (2) PT3042917T (es)
RS (3) RS59652B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI3042917T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US20170008955A1 (en) * 2014-02-03 2017-01-12 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
DK3166973T3 (da) * 2014-07-10 2020-04-06 Univ Zuerich Immunstimulerende monoklonale antistoffer mod human interleukin-2
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CA3032692A1 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
CN109641052A (zh) * 2016-08-18 2019-04-16 伊莱利利公司 BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
EP3723807B1 (en) 2017-12-14 2021-10-20 H. Lundbeck A/S Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN116693686A (zh) * 2018-02-11 2023-09-05 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
JP2021516682A (ja) * 2018-03-13 2021-07-08 スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． 破傷風神経毒素に結合する単一ドメイン抗体
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JOP20210265A1 (ar) * 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
KR20230078748A (ko) * 2020-10-02 2023-06-02 일라이 릴리 앤드 캄파니 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
AU2022371475A1 (en) 2021-10-22 2024-05-09 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
EP4422751A1 (en) 2021-10-29 2024-09-04 Eli Lilly and Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
CN118475610A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
MX2024005146A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a interleucina-34.
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
EP4558166A1 (en) * 2022-07-21 2025-05-28 Eli Lilly and Company Pharmaceutical solutions of anti-n3 pglu a beta antibodies and uses thereof
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228315A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025237397A1 (zh) * 2024-05-16 2025-11-20 江苏恒瑞医药股份有限公司 抗N3pGlu Aβ抗体及其医药用途
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026055601A1 (en) 2024-09-09 2026-03-12 Eli Lilly And Company METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
SI1720909T1 (sl) * 2004-02-23 2012-01-31 Lilly Co Eli Anti-abeta protitelo
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
CN102123726A (zh) 2008-06-12 2011-07-13 阿费里斯股份公司 用于治疗与帕金森氏病有关的症状的化合物
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
RS59652B1 (sr) 2020-01-31
BR112013004056A2 (pt) 2020-08-04
HRP20192233T1 (hr) 2020-03-06
LT3339323T (lt) 2020-02-10
LT3042917T (lt) 2018-05-10
PT3042917T (pt) 2018-05-02
IL224030B (en) 2022-04-01
JP2013536191A (ja) 2013-09-19
PE20130817A1 (es) 2013-07-18
ME02352B (me) 2016-06-20
SI3339323T1 (sl) 2019-12-31
FR25C1055I1 (fr) 2026-03-06
FIC20250038I1 (fi) 2025-12-18
EA201270813A1 (ru) 2013-05-30
EP3042917A1 (en) 2016-07-13
CA2805114A1 (en) 2012-02-16
JP6395755B2 (ja) 2018-09-26
MY163521A (en) 2017-09-15
LTPA2026504I1 (es) 2026-02-10
PL3042917T3 (pl) 2018-07-31
ES2664128T3 (es) 2018-04-18
HRP20180616T1 (hr) 2018-07-13
PL3339323T3 (pl) 2020-05-18
NZ606095A (en) 2014-11-28
EP3042917B1 (en) 2018-02-21
CL2013000390A1 (es) 2014-03-21
CN103068848A (zh) 2013-04-24
HK1180703A1 (zh) 2013-10-25
IL285226A (en) 2021-09-30
MX2013001716A (es) 2013-10-28
BR112013004056B8 (pt) 2022-10-18
ME03661B (me) 2020-07-20
CY1120144T1 (el) 2018-12-12
IL285226B2 (en) 2023-02-01
SI2603523T1 (sl) 2016-04-29
EP3339323A1 (en) 2018-06-27
CN105111308A (zh) 2015-12-02
EP3339323B1 (en) 2019-11-13
SG10201509330XA (en) 2015-12-30
AU2011289629A1 (en) 2013-02-14
KR20130051989A (ko) 2013-05-21
HRP20160151T1 (hr) 2016-03-11
JP2016179985A (ja) 2016-10-13
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
HUE037524T2 (hu) 2018-09-28
HUE028678T2 (en) 2016-12-28
RS54685B1 (sr) 2016-08-31
ECSP13012436A (es) 2013-03-28
NO3042917T3 (es) 2018-07-21
NZ626665A (en) 2016-04-29
GT201300036A (es) 2014-07-16
US20130142806A1 (en) 2013-06-06
SI3042917T1 (en) 2018-04-30
ZA201300437B (en) 2014-06-25
UA107600C2 (uk) 2015-01-26
CA2805114C (en) 2017-12-05
ME03032B (me) 2018-10-20
CO6670526A2 (es) 2013-05-15
DOP2013000029A (es) 2013-03-15
BR112013004056B1 (pt) 2022-05-17
WO2012021469A1 (en) 2012-02-16
NL301359I2 (nl) 2026-02-10
MX355268B (es) 2018-04-11
DK2603523T3 (en) 2016-03-21
ES2764728T3 (es) 2020-06-04
AU2011289629B2 (en) 2014-07-03
PL2603523T3 (pl) 2016-07-29
MX342782B (es) 2016-10-12
NO2025056I1 (no) 2025-12-11
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
US8961972B2 (en) 2015-02-24
CY1122458T1 (el) 2021-01-27
MY181969A (en) 2021-01-15
DK3042917T3 (en) 2018-04-23
US20140065138A1 (en) 2014-03-06
DK3339323T3 (da) 2020-01-20
CN105111308B (zh) 2019-03-12
IL285226B (en) 2022-10-01
US8679498B2 (en) 2014-03-25
EA023021B1 (ru) 2016-04-29
MA34461B1 (fr) 2013-08-01
JP5980207B2 (ja) 2016-08-31
RS57026B1 (sr) 2018-05-31
PH12013500277A1 (en) 2017-04-21
EP2603523B1 (en) 2016-01-27
CN103068848B (zh) 2015-11-25
PT3339323T (pt) 2020-01-14

Similar Documents

Publication Publication Date Title
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES2656000T3 (es) Anticuerpos frente a CGRP
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RU2013113933A (ru) Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
JP2018021031A5 (es)
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ740221A (en) St2l antagonists and methods of use